CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers and 35% of the non-acute market. Through this agreement, Vizient members now have increased access to Vibativ's new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy.

"We're pleased to expand availability of the new Vibativ 4-Vial Starter Pak for Vizient-contracted providers, supporting the cost-efficient delivery of our potent antibiotic in hospitals, infusion centers and outpatient centers nationwide," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.

Vibativ is an FDA-approved injectable antibiotic indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA.

In addition to the Vibativ 4-Vial Starter Pak, the Vibativ 12-vial carton is also available to Vizient provider clients through several distribution channels. For ordering information, please visitwww.vibativ.com/order.

For medical questions or educational needs, please contact Cumberland Pharmaceuticals Medical Affairs at[email protected].

Vibativ®(telavancin) injection was discovered in a research program dedicated to finding new antibiotics for serious infections due toStaphylococcus aureus (S. aureus)and other Gram-positive bacteria, including MRSA and MSSA. Vibativ is a once-daily, injectable lipoglycopeptide antibiotic within vitropotency, bactericidal activity within six hours and penetration into target infection sites. The drug is approved in the U.S. for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates ofS. aureuswhen alternative treatments are not suitable.

In addition, Vibativ is approved for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, includingS. aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling also describes the use of Vibativ in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. The product's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients withS. aureusinfections studied to date. Importantly, these studies demonstrated significantly higher cure rates for Vibativ as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen orS. aureuswith vancomycin MIC ≥1 µg/mL. Additionally, there is extensive and well-documented evidence of the drug'sin vitropotency andin vivoactivity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

For full prescribing information, including important safety information, visitwww.vibativ.com.

The company also has Phase II clinical studies evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy, systemic sclerosis and idiopathic pulmonary fibrosis.

For more information onCumberland'sapproved products, including full prescribing information, please visit the individual product websites, which can be found on the company's website:www.cumberlandpharma.com.

This press release contains forward-looking statements, which are subject to certain risks and reflectCumberland'scurrent views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases ofCumberland'soperations are subject to factors outside of its control, and any one or combination of these factors could materially affectCumberland'soperation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produceCumberland'sproducts on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.